Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hubei Univ. of Medicine EGFR compound 10a: sourced facts only. name: "It is worth mentioning that the coumarin-furo[2,3-d]pyrimidone combination 10a showed excellent inhibition of the EGFR enzymatic activity with IC50 = 1.53 μM and 90% inhibition at 10 μM concentration." [PMID:38784474]; target: "It is worth mentioning that the coumarin-furo[2,3-d]pyrimidone combination 10a showed excellent inhibition of the EGFR enzymatic activity with IC50 = 1.53 μM and 90% inhibition at 10 μM concentration." [PMID:38784474]; developer: "School of Pharmacy, Hubei University of Medicine Shiyan 442000 Hubei China [email protected]." [PMID:38784474]; stage: "The coumarin-furo[2,3-d]pyrimidone combination 10a exhibited significant inhibitory activity against HepG2 cells with IC50 = 7.72 ± 1.56 μM, which is better than those of gefitinib and sorafenib." [PMID:38784474]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hubei Univ. of Medicine EGFR compound 10a.